The proliferation of cheaper generic drugs and more competition has already begun to bring down prices on weight-loss ...

Novo Nordisk cut its 2026 outlook after missing 2025 estimates, while Eli Lilly heads into earnings with a focus on Medicare ...

Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

Novo Nordisk A/S faces a margin crisis as oral Wegovy hits injectable profits. Click for this post-earnings update and see ...

Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...

An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% ...

Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for ...

Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government’s push to cut drug prices in country, will contribute to the decline, the company said. The warning ...

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...